<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479388</url>
  </required_header>
  <id_info>
    <org_study_id>0524A-067</org_study_id>
    <secondary_id>2007_521</secondary_id>
    <nct_id>NCT00479388</nct_id>
  </id_info>
  <brief_title>Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a 12-Week clinical trial in patients with Primary hypercholesterolemia or mixed
      dyslipidemia to study the effects of ER niacin/laropiprant on lipids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at Week 12</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1216</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <condition>Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: simvastatin</intervention_name>
    <description>simvastatin (20mg to 40mg) for 12 weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zocor®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>niacin (+) laropiprant</intervention_name>
    <description>One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0524A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: atorvastatin calcium</intervention_name>
    <description>atorvastatin calcium (20mg to 40mg) for 12 weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>atorvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 to 80 years of age with Primary hypercholesterolemia or mixed dyslipidemia

          -  Patients will be eligible for the study if their LDL-C values are within protocol
             specified range and meet other entry criteria

        Exclusion Criteria:

          -  Patient whose LDL-C values are not within protocol specified range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>(MedWatch - FDA maintained medical product safety Information)</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>(Merck: Patient &amp; Caregiver U.S. Product Web Site)</description>
  </link>
  <results_reference>
    <citation>Shah S, Ceska R, Gil-Extremera B, Paolini JF, Giezek H, Vandormael K, Mao A, McCrary Sisk C, Maccubbin D. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2010 May;64(6):727-38. doi: 10.1111/j.1742-1241.2010.02370.x.</citation>
    <PMID>20518948</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2007</study_first_submitted>
  <study_first_submitted_qc>May 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <results_first_submitted>June 9, 2009</results_first_submitted>
  <results_first_submitted_qc>June 9, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 31, 2009</results_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient In: 30-Jul-2007 Last Patient Last Visit: 10-Jul-2008
Investigators: 161 sites participated: Australia–5; Austria–4; Canada–11; Czech Republic–5; Denmark–4; France–10; Germany–24; Hungary–6; Israel–4; Italy–11; Netherlands–2; Norway–10; Poland–11; Russian Federation–7; South Africa–9; Spain–4; Sweden–17; United States–17</recruitment_details>
      <pre_assignment_details>Patients on atorvastatin (10mg) or simvastatin (10mg or 20mg) had a 2 week run-in of their statin. Naïve patients or patients on other statins were started on simvastatin (10 or 20mg) or atorvastatin (10mg) for a 6 week run-in. Patients were eligible to be randomized if their Visit 1 low density lipoprotein cholesterol values were above goal.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ER Niacin/Laropiprant + Run-in Statin</title>
          <description>One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.</description>
        </group>
        <group group_id="P2">
          <title>Run-in Statin Dose Doubled</title>
          <description>Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="606"/>
                <participants group_id="P2" count="610"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="474"/>
                <participants group_id="P2" count="537"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ER Niacin/Laropiprant + Run-in Statin</title>
          <description>One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.</description>
        </group>
        <group group_id="B2">
          <title>Run-in Statin Dose Doubled</title>
          <description>Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="606"/>
            <count group_id="B2" value="610"/>
            <count group_id="B3" value="1216"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="9.7"/>
                    <measurement group_id="B2" value="60.6" spread="9.8"/>
                    <measurement group_id="B3" value="60.5" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="289"/>
                    <measurement group_id="B3" value="593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="321"/>
                    <measurement group_id="B3" value="623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Heart Disease Risk Category by Goal</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Low Risk at Goal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Risk Not at Goal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Risk at Goal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Risk Not at Goal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Risk at Goal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Risk Not at Goal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipid Modification Type/Dose at Run-in</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Simvastatin 10 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="233"/>
                    <measurement group_id="B3" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Simvastatin 20 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atorvastatin 10 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Serum Glucose (FSG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108.3" spread="27.2"/>
                    <measurement group_id="B2" value="108.7" spread="27.7"/>
                    <measurement group_id="B3" value="108.5" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-density lipoprotein cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.89" spread="14.45"/>
                    <measurement group_id="B2" value="54.97" spread="13.91"/>
                    <measurement group_id="B3" value="54.93" spread="14.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-density lipoprotein cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117.55" spread="28.66"/>
                    <measurement group_id="B2" value="115.82" spread="28.37"/>
                    <measurement group_id="B3" value="116.68" spread="28.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides (TG)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136.00" lower_limit="46.00" upper_limit="594.00"/>
                    <measurement group_id="B2" value="124.00" lower_limit="42.00" upper_limit="852.00"/>
                    <measurement group_id="B3" value="130.00" lower_limit="42.00" upper_limit="852.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12</title>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ER Niacin/Laropiprant + Run-in Statin</title>
            <description>One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.</description>
          </group>
          <group group_id="O2">
            <title>Run-in Statin Dose Doubled</title>
            <description>Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12</title>
          <population>Full Analysis Set</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="595"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" lower_limit="-12.6" upper_limit="-7.4"/>
                    <measurement group_id="O2" value="-5.5" lower_limit="-7.4" upper_limit="-3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Repeated measures analysis</method>
            <method_desc>Study times: 4, 8 and 12 weeks. Terms: treatment-by-time, gender-by-time, baseline LDL-C-by-time and concomitant statin group-by-time interaction.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-4.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>-1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12</title>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>ER Niacin/Laropiprant + Run-in Statin</title>
            <description>One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.</description>
          </group>
          <group group_id="O2">
            <title>Run-in Statin Dose Doubled</title>
            <description>Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12</title>
          <population>Full Analysis Set</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="595"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="13.8" upper_limit="17.8"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-1.1" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>Repeated measures analysis</method>
            <method_desc>Study times: 4, 8 and 12 weeks. Terms: treatment-by-time, gender-by-time, baseline HDL-C-by-time and concomitant statin group-by-time interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>13.4</ci_lower_limit>
            <ci_upper_limit>17.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at Week 12</title>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Full Analysis Set With at Least one Post-Titration Visit Measurement</population>
        <group_list>
          <group group_id="O1">
            <title>ER Niacin/Laropiprant + Run-in Statin</title>
            <description>One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.</description>
          </group>
          <group group_id="O2">
            <title>Run-in Statin Dose Doubled</title>
            <description>Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at Week 12</title>
          <population>Full Analysis Set With at Least one Post-Titration Visit Measurement</population>
          <units>Percent</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="571"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.6" lower_limit="-21.0" upper_limit="-14.2"/>
                    <measurement group_id="O2" value="-4.0" lower_limit="-7.2" upper_limit="-0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>Repeated measures analysis</method>
            <method_desc>ANCOVA model based on Tukey’s normalized ranks with term for treatment, gender, concomitant statin group and Tukey's normal score of baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.2</ci_lower_limit>
            <ci_upper_limit>-11.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ER Niacin/Laropiprant + Run-in Statin</title>
          <description>One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.</description>
        </group>
        <group group_id="E2">
          <title>Run-in Statin Dose Doubled</title>
          <description>Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14"/>
                <counts group_id="E2" subjects_affected="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="249"/>
                <counts group_id="E2" subjects_affected="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Cardiac discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Retinal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Balanitis candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Mycoplasma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Gastric pH decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Liver palpable subcostal</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Pulse abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Impaired fasting glucose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Menstruation delayed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Dandruff</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Acrodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="609"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="609"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

